← Search & browse all drugs
CARDIOVASCULAR SYSTEM › DIURETICS › DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION › Low-ceiling diuretics and potassium-sparing agents
epitizide and potassium-sparing agents
C03EA03
Forms & Strengths
- Fixed-dose combination tablets containing epitizide (thiazide diuretic) and a potassium-sparing agent (e.g., spironolactone or triamterene)
- Available in various regional proprietary dosage strengths
Adult Dosing
- Hypertension: 1 tablet daily, adjusted based on clinical response and electrolyte monitoring
- Edema: 1 to 2 tablets daily in divided doses or as a single daily dose
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
- Use in children is generally not recommended
Indications
- Management of essential hypertension
- Treatment of edema associated with congestive heart failure, hepatic cirrhosis, or nephrotic syndrome
- Prevention of thiazide-induced hypokalemia through the inclusion of a potassium-sparing agent
Mechanism of Action
- Epitizide inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing excretion of sodium, water, and potassium
- Potassium-sparing component acts via competitive aldosterone antagonism or direct epithelial sodium channel blockade in the late distal tubule and collecting duct, reducing potassium excretion
Contraindications
- Anuria or acute renal failure
- Severe renal impairment (creatinine clearance < 30 mL/min) or progressive oliguria
- Hyperkalemia (serum potassium > 5.0 mEq/L)
- Concomitant use of other potassium-sparing agents, potassium supplements, or aldosterone antagonists
- Hypersensitivity to thiazides, sulfonamide-derived drugs, or the potassium-sparing component
- Addison's disease
Adverse Reactions
- Hyperkalemia
- Hyponatremia and hypochloremia
- Hypotension and orthostatic hypotension
- Hyperuricemia and gout exacerbation
- Hyperglycemia and dyslipidemia
- Gastrointestinal disturbances (nausea, vomiting, diarrhea)
- Dizziness, headache, and paresthesia
- Photosensitivity and rash
Drug Interactions
- ACE inhibitors, ARBs, and direct renin inhibitors increase the risk of severe hyperkalemia
- NSAIDs may diminish the antihypertensive and diuretic efficacy and increase nephrotoxicity risk
- Lithium co-administration decreases lithium renal clearance, increasing toxicity risk
- Other antihypertensive agents potentiate blood pressure-lowering effects
- Corticosteroids or ACTH increase the risk of severe electrolyte depletion, particularly hypokalemia (if potassium-sparing effect is overcome)
- Skeletal muscle relaxants (nondepolarizing) may experience enhanced responsiveness
Curated Content: Needs Vetting Before Put to Clinical Use